It may be noted that the Pfizer-BioNTech Covid-19 vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), and has only been authorised for emergency use by FDA under an Emergency Use Authorisation (EUA) to prevent coronavirus disease (COVID-19) for use in individuals 16 years of age and older.
Despite the positive results, the authors note that there is not enough evidence to conclude whether the vaccine impacts the transmission of SARS-CoV-2, the virus that causes COVID-19.
Speaking on Punjab's vaccination preparedness, Mr. Sidhu said the State is fully prepared for the vaccination drive and has a capacity of vaccinating 4 lakh persons a day. If all goes as per the plan, the Punjab government aims to provide vaccine dose to a target population of about 70 lakh in phase manner for free once it is made available by the Central government.
According to the federal agency, these mRNA vaccines are not interchangeable with each other or with other COVID-19 vaccine products. Here are the biggest developments from the last 10 days. "We're making an assumption that the public is just going to listen and come in and get the vaccine", she said. With different ingredients in each vaccine, it's possible people will not benefit as much from a second shot.
Minister Donnelly confirmed some of the COVID-19 vaccines will be held back for the second doses. This later increased to 20,000 before being increased again to 35,000 this Monday morning.
Five Indian cricket players in isolation after restaurant visit
The Australian and Indian cricket boards are investigating the allegations which point towards a breach of biosecurity protocols. Earlier, India vice-captain Rohit Sharma hit the batting nets for the first time since arriving in Australia on Friday.
Stephen Donnelly added that the country will start receiving 40,000 Pfizer vaccines per week in January and February.
The society called on the Government to implement a robust programme of immune monitoring to assess how altering the dosing schedule impacts efficacy of both vaccines that have been approved for use in the United Kingdom, with rapid modification of dosing schedules as appropriate.
He admitted that the delivery across Europe has been "somewhat of a mixed bag" but that Ireland is watching supply issues in other countries closely.
But Dr Mary Ramsay, the head of immunisations at PHE, dismissed the idea it would be used widely, saying: "We do not recommend mixing the Covid-19 vaccines - if your first dose is the Pfizer vaccine you should not be given the AstraZeneca vaccine for your second dose and vice-versa".
Kyriakides noted that Brussels had provided €100 million ($121 million) to German firm BioNTech, which developed a vaccine with USA giant Pfizer, to help build production capacity.